Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Deoxycytidine"" wg kryterium: Temat


Tytuł :
Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study.
Autorzy :
Mi M; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhang C
Liu Z
Wang Y
Li J
Zhang L
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Dec 04; Vol. 99 (49), pp. e23412.
Typ publikacji :
Comparative Study; Journal Article; Observational Study
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Deoxycytidine/*analogs & derivatives
Hodgkin Disease/*drug therapy
Lymphoma, Non-Hodgkin/*drug therapy
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carboplatin/therapeutic use ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Cisplatin/therapeutic use ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Deoxycytidine/therapeutic use ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Dexamethasone/therapeutic use ; Etoposide/administration & dosage ; Etoposide/adverse effects ; Etoposide/therapeutic use ; Female ; Humans ; Ifosfamide/administration & dosage ; Ifosfamide/adverse effects ; Ifosfamide/therapeutic use ; Male ; Middle Aged ; Recurrence ; Salvage Therapy ; Young Adult
SCR Protocol :
GDP protocol; ICE protocol 1
Czasopismo naukowe
Tytuł :
Diltiazem potentiates the cytotoxicity of gemcitabine and 5-fluorouracil in PANC-1 human pancreatic cancer cells through inhibition of P-glycoprotein.
Autorzy :
El-Mahdy HA; Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Al-Azhar University, Nasr City 11231, Cairo, Egypt.
El-Husseiny AA; Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Al-Azhar University, Nasr City 11231, Cairo, Egypt. Electronic address: .
Kandil YI; Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Al-Azhar University, Nasr City 11231, Cairo, Egypt; Pharmacological and Diagnostic Research Centre, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman 19328, Jordan.
Gamal El-Din AM; Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Al-Azhar University, Nasr City 11231, Cairo, Egypt.
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2020 Dec 01; Vol. 262, pp. 118518. Date of Electronic Publication: 2020 Oct 01.
Typ publikacji :
Journal Article
MeSH Terms :
Deoxycytidine/*analogs & derivatives
Diltiazem/*pharmacology
Fluorouracil/*pharmacology
Pancreatic Neoplasms/*drug therapy
ATP Binding Cassette Transporter, Subfamily B/antagonists & inhibitors ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Apoptosis/drug effects ; Calcium Channel Blockers/administration & dosage ; Calcium Channel Blockers/pharmacology ; Cell Cycle Checkpoints/drug effects ; Cell Line, Tumor ; Cell Survival/drug effects ; Deoxycytidine/administration & dosage ; Deoxycytidine/pharmacology ; Diltiazem/administration & dosage ; Drug Synergism ; Fluorouracil/administration & dosage ; Humans ; Pancreatic Neoplasms/pathology
Czasopismo naukowe
Tytuł :
Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue.
Autorzy :
Cojocaru E; Sarcoma Unit, The Royal Marsden Hospital, London, U.K.
Thway K; Sarcoma Unit, The Royal Marsden Hospital, London, U.K.; The Institute of Cancer Research, Chester Beatty Laboratories, London, U.K.
Fisher C; The Institute of Cancer Research, Chester Beatty Laboratories, London, U.K.; Department of Musculoskeletal Pathology, University Hospitals Birmingham, Birmingham, U.K.
Messiou C; The Institute of Cancer Research, Chester Beatty Laboratories, London, U.K.; Radiology Department, The Royal Marsden Hospital, London, U.K.
Zaidi S; Sarcoma Unit, The Royal Marsden Hospital, London, U.K.; The Institute of Cancer Research, Chester Beatty Laboratories, London, U.K.
Miah AB; Sarcoma Unit, The Royal Marsden Hospital, London, U.K.; The Institute of Cancer Research, Chester Beatty Laboratories, London, U.K.
Benson C; Sarcoma Unit, The Royal Marsden Hospital, London, U.K.
Gennatas S; Sarcoma Unit, The Royal Marsden Hospital, London, U.K.
Huang P; The Institute of Cancer Research, Chester Beatty Laboratories, London, U.K.
Jones RL; Sarcoma Unit, The Royal Marsden Hospital, London, U.K. .; The Institute of Cancer Research, Chester Beatty Laboratories, London, U.K. .
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2020 Dec; Vol. 40 (12), pp. 7003-7007.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Antimetabolites, Antineoplastic/*therapeutic use
Deoxycytidine/*analogs & derivatives
Sarcoma, Clear Cell/*drug therapy
Soft Tissue Neoplasms/*drug therapy
Adult ; Antimetabolites, Antineoplastic/pharmacology ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; Female ; Humans ; Male ; Middle Aged
Czasopismo naukowe
Tytuł :
MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells.
Autorzy :
Masetto F; Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy.
Chegaev K; Department of Drug Science and Technology, University of Turin, Italy.
Gazzano E; Department of Oncology, University of Turin, Italy.
Mullappilly N; Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy.
Rolando B; Department of Drug Science and Technology, University of Turin, Italy.
Arpicco S; Department of Drug Science and Technology, University of Turin, Italy.
Fruttero R; Department of Drug Science and Technology, University of Turin, Italy.
Riganti C; Department of Oncology, University of Turin, Italy. Electronic address: .
Donadelli M; Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy. Electronic address: .
Pokaż więcej
Źródło :
Biochimica et biophysica acta. Molecular cell research [Biochim Biophys Acta Mol Cell Res] 2020 Dec; Vol. 1867 (12), pp. 118824. Date of Electronic Publication: 2020 Aug 21.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma/*drug therapy
Deoxycytidine/*analogs & derivatives
Multidrug Resistance-Associated Proteins/*genetics
Pancreatic Neoplasms/*drug therapy
Adenocarcinoma/genetics ; Adenocarcinoma/pathology ; Apoptosis/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Deoxycytidine/chemistry ; Deoxycytidine/pharmacology ; Drug Resistance, Neoplasm/drug effects ; Humans ; Liposomes/chemistry ; Liposomes/pharmacology ; Nitric Oxide/metabolism ; Pancreatic Neoplasms/genetics ; Pancreatic Neoplasms/pathology
Czasopismo naukowe
Tytuł :
Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia.
Autorzy :
Wander P; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
Cheung LC; Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia.; School of Pharmacy and Biomedical Sciences, Curtin University, Perth, WA, Australia.
Pinhanҫos SS; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; CNC-Center for Neurosciences and Cell Biology, University of Coimbra, Coimbra, Portugal.
Jones L; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Kerstjens M; Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
Arentsen-Peters STCJM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Singh S; Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia.
Chua GA; Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia.
Castro PG; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Schneider P; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Dolman MEM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Koopmans B; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Molenaar JJ; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Pieters R; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Zwaan CM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
Kotecha RS; Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia. .; School of Pharmacy and Biomedical Sciences, Curtin University, Perth, WA, Australia. .; Department of Haematology and Oncology, Perth Children's Hospital, Perth, WA, Australia. .
Stam RW; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2020 Nov; Vol. 34 (11), pp. 2898-2902. Date of Electronic Publication: 2020 Jun 02.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Rearrangement*
Antimetabolites, Antineoplastic/*pharmacology
Deoxycytidine/*analogs & derivatives
Myeloid-Lymphoid Leukemia Protein/*genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*genetics
Animals ; Antimetabolites, Antineoplastic/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; Disease Management ; Disease Models, Animal ; Drug Evaluation, Preclinical ; Genetic Predisposition to Disease ; Humans ; Infant ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology
Czasopismo naukowe
Tytuł :
Paracrine HGF promotes EMT and mediates the effects of PSC on chemoresistance by activating c-Met/PI3K/Akt signaling in pancreatic cancer in vitro.
Autorzy :
Xu J; Department of Gastrointestinal Surgery, the Affiliated Hospital of Qingdao University, Qingdao, China.
Liu S; Department of Gastrointestinal Surgery, the Affiliated Hospital of Qingdao University, Qingdao, China.
Yang X; Department of Gastrointestinal Surgery, Yidu Central Hospital, Weifang, China.
Cao S; Department of Gastrointestinal Surgery, the Affiliated Hospital of Qingdao University, Qingdao, China.
Zhou Y; Department of Gastrointestinal Surgery, the Affiliated Hospital of Qingdao University, Qingdao, China. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2020 Dec 15; Vol. 263, pp. 118523. Date of Electronic Publication: 2020 Oct 08.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Resistance, Neoplasm*
Epithelial-Mesenchymal Transition*
Deoxycytidine/*analogs & derivatives
Gene Expression Regulation, Neoplastic/*drug effects
Hepatocyte Growth Factor/*pharmacology
Pancreatic Neoplasms/*pathology
Pancreatic Stellate Cells/*pathology
Antimetabolites, Antineoplastic/pharmacology ; Apoptosis ; Cell Proliferation ; Deoxycytidine/pharmacology ; Humans ; Pancreatic Neoplasms/drug therapy ; Pancreatic Neoplasms/genetics ; Pancreatic Neoplasms/metabolism ; Pancreatic Stellate Cells/drug effects ; Pancreatic Stellate Cells/metabolism ; Paracrine Communication ; Phosphatidylinositol 3-Kinases/genetics ; Phosphatidylinositol 3-Kinases/metabolism ; Proto-Oncogene Proteins c-akt/genetics ; Proto-Oncogene Proteins c-akt/metabolism ; Proto-Oncogene Proteins c-met/genetics ; Proto-Oncogene Proteins c-met/metabolism ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł :
Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study.
Autorzy :
Wei C; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.
Cao X; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.
Zhang W; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.
Zhang Y; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.
Wang W; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.
Zhang L; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.
Yang C; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.
Feng J; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.
Cai H; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.
Chen M; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.
Mao Y; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.
Zhou D; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Dec; Vol. 99 (12), pp. 2801-2809. Date of Electronic Publication: 2020 May 13.
Typ publikacji :
Clinical Trial, Phase II; Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Asparaginase/*administration & dosage
Cisplatin/*administration & dosage
Deoxycytidine/*analogs & derivatives
Lymphoma, Extranodal NK-T-Cell/*drug therapy
Methotrexate/*administration & dosage
Nose Neoplasms/*drug therapy
Polyethylene Glycols/*administration & dosage
Adult ; Aged ; Deoxycytidine/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Lymphoma, Extranodal NK-T-Cell/diagnostic imaging ; Lymphoma, Extranodal NK-T-Cell/mortality ; Male ; Middle Aged ; Nose Neoplasms/diagnostic imaging ; Nose Neoplasms/mortality ; Prospective Studies ; Survival Rate/trends ; Young Adult
Czasopismo naukowe
Tytuł :
Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture.
Autorzy :
Zhang YN; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.; University of Chinese Academy of Sciences, Beijing, People's Republic of China.
Zhang QY; The Joint Center of Translational Precision Medicine, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou, People's Republic of China.; The Joint Center of Translational Precision Medicine, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People's Republic of China.
Li XD; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.; School of Medicine, Hunan Normal University, Changsha, People's Republic of China.
Xiong J; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.
Xiao SQ; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.
Wang Z; Drug Discovery Center for Infectious Disease, Nankai University, Tianjin, People's Republic of China.
Zhang ZR; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.; University of Chinese Academy of Sciences, Beijing, People's Republic of China.
Deng CL; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.
Yang XL; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.
Wei HP; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.
Yuan ZM; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.
Ye HQ; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.
Zhang B; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.; The Joint Center of Translational Precision Medicine, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou, People's Republic of China.; The Joint Center of Translational Precision Medicine, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People's Republic of China.; Drug Discovery Center for Infectious Disease, Nankai University, Tianjin, People's Republic of China.
Pokaż więcej
Źródło :
Emerging microbes & infections [Emerg Microbes Infect] 2020 Dec; Vol. 9 (1), pp. 1170-1173.
Typ publikacji :
Letter
MeSH Terms :
Alkaloids/*pharmacology
Amaryllidaceae Alkaloids/*pharmacology
Antiviral Agents/*pharmacology
Betacoronavirus/*drug effects
Deoxycytidine/*analogs & derivatives
Phenanthridines/*pharmacology
Virus Replication/*drug effects
Animals ; Betacoronavirus/growth & development ; Betacoronavirus/metabolism ; Cell Survival/drug effects ; Chlorocebus aethiops ; Chloroquine/pharmacology ; Deoxycytidine/pharmacology ; Dose-Response Relationship, Drug ; Drug Combinations ; Drug Synergism ; SARS-CoV-2 ; Vero Cells
Opinia redakcyjna
Tytuł :
Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer.
Autorzy :
Uehara M; Division of Translational and Clinical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Domoto T; Division of Translational and Clinical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Takenaka S; Division of Translational and Clinical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.; Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Bolidong D; Division of Translational and Clinical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Takeuchi O; Biomedical Laboratory, Department of Research, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
Miyashita T; Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.; Department of Surgical Oncology, Kanazawa Medical University, Ishikawa, Japan.
Minamoto T; Division of Translational and Clinical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2020 Dec; Vol. 111 (12), pp. 4405-4416. Date of Electronic Publication: 2020 Oct 12.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Resistance, Neoplasm*
Antimetabolites, Antineoplastic/*pharmacology
Deoxycytidine/*analogs & derivatives
Glycogen Synthase Kinase 3 beta/*physiology
Pancreatic Neoplasms/*drug therapy
Animals ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Cyclin D1/metabolism ; Deoxycytidine/pharmacology ; E2F1 Transcription Factor/metabolism ; Glycogen Synthase Kinase 3 beta/antagonists & inhibitors ; Heterografts ; Humans ; Mice ; Mice, Nude ; Pancreatic Neoplasms/metabolism ; Phosphorylation ; Retinoblastoma Protein/metabolism ; Ribonucleoside Diphosphate Reductase/metabolism ; Thymidine Kinase/metabolism ; Thymidylate Synthase/metabolism ; Transcription, Genetic
Czasopismo naukowe
Tytuł :
Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells.
Autorzy :
Wei X; Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA 22903.
Yang J; Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA 22903.
Adair SJ; Department of Surgery, University of Virginia School of Medicine, Charlottesville, VA 22903.
Ozturk H; Feinberg School of Medicine, Robert Lurie Comprehensive Cancer Center, Department of Obstetrics and Gynecology, The Northwestern University, Chicago, IL 60611.
Kuscu C; Transplant Research Institute, University of Tennessee Health Science Center, Memphis, TN 38163.
Lee KY; Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA 22903.
Kane WJ; Department of Surgery, University of Virginia School of Medicine, Charlottesville, VA 22903.
O'Hara PE; Department of Surgery, University of Virginia School of Medicine, Charlottesville, VA 22903.
Liu D; Department of Surgery, University of Virginia School of Medicine, Charlottesville, VA 22903.
Demirlenk YM; Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA 22903.
Habieb AH; Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA 22903.
Yilmaz E; Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA 22903.
Dutta A; Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA 22903.
Bauer TW; Department of Surgery, University of Virginia School of Medicine, Charlottesville, VA 22903.
Adli M; Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA 22903; .; Feinberg School of Medicine, Robert Lurie Comprehensive Cancer Center, Department of Obstetrics and Gynecology, The Northwestern University, Chicago, IL 60611.
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2020 Nov 10; Vol. 117 (45), pp. 28068-28079. Date of Electronic Publication: 2020 Oct 23.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Protein-Arginine N-Methyltransferases*/antagonists & inhibitors
Protein-Arginine N-Methyltransferases*/genetics
Protein-Arginine N-Methyltransferases*/metabolism
Antineoplastic Agents/*pharmacology
Deoxycytidine/*analogs & derivatives
Pancreatic Neoplasms/*metabolism
Animals ; CRISPR-Cas Systems/genetics ; Cell Line, Tumor ; Cell Survival/drug effects ; Deoxycytidine/pharmacology ; Drug Development ; Gene Knockout Techniques ; Humans ; Mice, Nude ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
2'-Fluoro-2'-deoxycytidine inhibits murine norovirus replication and synergizes MPA, ribavirin and T705.
Autorzy :
Yu P; Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Room Na-1005, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands.
Wang Y; Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Room Na-1005, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands.
Li Y; Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Room Na-1005, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands.
Li Y; Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Room Na-1005, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands.
Miao Z; Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Room Na-1005, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands.
Peppelenbosch MP; Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Room Na-1005, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands.
Pan Q; Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Room Na-1005, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands. .
Pokaż więcej
Źródło :
Archives of virology [Arch Virol] 2020 Nov; Vol. 165 (11), pp. 2605-2613. Date of Electronic Publication: 2020 Aug 08.
Typ publikacji :
Journal Article
MeSH Terms :
Antiviral Agents/*pharmacology
Deoxycytidine/*analogs & derivatives
Norovirus/*drug effects
Virus Replication/*drug effects
Amides/pharmacology ; Animals ; Caliciviridae Infections/drug therapy ; Caliciviridae Infections/virology ; Cell Line ; Deoxycytidine/pharmacology ; Humans ; Mice ; Mycophenolic Acid/pharmacology ; Norovirus/physiology ; Pyrazines/pharmacology ; RAW 264.7 Cells ; Ribavirin/pharmacology ; Virus Replication/physiology
Czasopismo naukowe
Tytuł :
Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice.
Autorzy :
Thompson BR; Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA.
Shi J; Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA.
Zhu HJ; Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA.
Smith DE; Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: .
Pokaż więcej
Źródło :
Biochemical pharmacology [Biochem Pharmacol] 2020 Oct; Vol. 180, pp. 114127. Date of Electronic Publication: 2020 Jun 27.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Amino Acids/*chemistry
Antimetabolites, Antineoplastic/*pharmacokinetics
Deoxycytidine/*analogs & derivatives
Prodrugs/*pharmacokinetics
Administration, Oral ; Animals ; Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/blood ; Antimetabolites, Antineoplastic/chemistry ; Biological Availability ; Deoxycytidine/administration & dosage ; Deoxycytidine/blood ; Deoxycytidine/chemistry ; Deoxycytidine/pharmacokinetics ; Drug Stability ; Esters ; Injections, Intravenous ; Jejunum/metabolism ; Mice ; Mice, Inbred C57BL ; Molecular Structure ; Prodrugs/administration & dosage ; Prodrugs/chemistry
Czasopismo naukowe
Tytuł :
Exploring the action of RGDV-gemcitabine on tumor metastasis, tumor growth and possible action pathway.
Autorzy :
Zhang X; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, NO. 10, Youanmenwaixitoutiao, Fengtai District, Beijing, 100069, China.; Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China.
Zhang J; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, NO. 10, Youanmenwaixitoutiao, Fengtai District, Beijing, 100069, China.; Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China.
Liu W; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, NO. 10, Youanmenwaixitoutiao, Fengtai District, Beijing, 100069, China.; Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China.
Wang Y; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, NO. 10, Youanmenwaixitoutiao, Fengtai District, Beijing, 100069, China.; Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China.
Wu J; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, NO. 10, Youanmenwaixitoutiao, Fengtai District, Beijing, 100069, China.; Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China.
Zhao S; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, NO. 10, Youanmenwaixitoutiao, Fengtai District, Beijing, 100069, China.; Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China.
Zhao M; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, NO. 10, Youanmenwaixitoutiao, Fengtai District, Beijing, 100069, China. .; Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China. .; Beijing Laboratory of Biomedical Materials and Key Laboratory of Biomedical Materials of Natural Macromolecules, Department of Biomaterials, College of Materials Science and Engineering, Beijing University of Chemical Technology, Beijing, 100026, China. .
Peng S; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, NO. 10, Youanmenwaixitoutiao, Fengtai District, Beijing, 100069, China. .; Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Sep 25; Vol. 10 (1), pp. 15729. Date of Electronic Publication: 2020 Sep 25.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Deoxycytidine/*analogs & derivatives
Lung Neoplasms/*drug therapy
Lung Neoplasms/*secondary
Oligopeptides/*administration & dosage
A549 Cells ; Animals ; Cell Adhesion ; Cell Line, Tumor ; Cell Movement/drug effects ; Deoxycytidine/administration & dosage ; Deoxycytidine/pharmacology ; Dose-Response Relationship, Drug ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Interleukin-8/metabolism ; Lung Neoplasms/metabolism ; Matrix Metalloproteinase 2/metabolism ; Matrix Metalloproteinase 9/metabolism ; Mice, Inbred C57BL ; Microscopy, Atomic Force ; Oligopeptides/pharmacology ; Tumor Necrosis Factor-alpha/metabolism ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model.
Autorzy :
Shankara Narayanan JS; Moores Cancer Center, University of California San Diego, CA.
Vicente DA; Moores Cancer Center, University of California San Diego, CA.
Ray P; Moores Cancer Center, University of California San Diego, CA.
Chai LF; Immuno-oncology Institute and Department of Medicine, Roger Williams Medical Center, Providence, RI; Department of Surgery, Boston University School of Medicine, Boston, MA.
Erdem S; Moores Cancer Center, University of California San Diego, CA.
Carr MJ; Moores Cancer Center, University of California San Diego, CA.
Capacio BA; Moores Cancer Center, University of California San Diego, CA.
Cox BF; TriSalus Life Sciences, Westminster, CO.
Jaroch DB; TriSalus Life Sciences, Westminster, CO.
Katz SC; Immuno-oncology Institute and Department of Medicine, Roger Williams Medical Center, Providence, RI; Department of Surgery, Boston University School of Medicine, Boston, MA.
White RR; Moores Cancer Center, University of California San Diego, CA. Electronic address: .
Pokaż więcej
Źródło :
Surgery [Surgery] 2020 Sep; Vol. 168 (3), pp. 448-456. Date of Electronic Publication: 2020 Jun 30.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antimetabolites, Antineoplastic/*administration & dosage
Carcinoma, Pancreatic Ductal/*drug therapy
Deoxycytidine/*analogs & derivatives
Infusions, Intralesional/*methods
Pancreatic Neoplasms/*drug therapy
Animals ; Antimetabolites, Antineoplastic/pharmacokinetics ; Carcinoma, Pancreatic Ductal/pathology ; Cell Line, Tumor/transplantation ; Deoxycytidine/administration & dosage ; Deoxycytidine/pharmacokinetics ; Disease Models, Animal ; Humans ; Infusions, Intravenous/methods ; Male ; Mice ; Pancreas/blood supply ; Pancreas/pathology ; Pancreatic Neoplasms/pathology ; Pressure ; Tissue Distribution
Czasopismo naukowe
Tytuł :
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).
Autorzy :
Rinaldi Y; Department of Hepato-gastroenterology, European Hospital, Marseille, France.
Pointet AL; Department of Hepato-gastroenterology, Georges Pompidou European Hospital, Paris, France.
Khemissa Akouz F; Department of Hepato-gastroenterology, Saint Jean Hospital, Perpignan, France.
Le Malicot K; Biostatistics Department, Francophone Federation of Digestive Cancerology, EPICAD INSERM LNC-UMR 1231, University of Burgundy and Franche Comté, Dijon, France.
Wahiba B; Department of Hepato-gastroenterology, European Hospital, Marseille, France.
Louafi S; Department of Oncology, Sud Francilien Hospital Center, Corbeil-Essonnes, France.
Gratet A; Oncology and Hematology ONCOSUD Unit, Clinic Pasteur, Toulouse, France.
Miglianico L; Department of Radiotherapy, Private Hospital Center, Saint-Grégoire, France.
Laharie H; Department of Oncology and Radiotherapy, Clinic Tivoli, Bordeaux, France.
Bouhier Leporrier K; Department of Hepato-gastroenterology, University Hospital, Caen, France.
Thirot Bidault A; Department of Hepato-gastroenterology, Private Hospital, Antony, France.
Texereau P; Department of Hepato-gastroenterology, Layne Hospital, Mont-De-Marsan, France.
Coriat R; Department of Hepato-gastroenterology, Cochin Hospital, APHP, Paris, France.
Terrebonne E; Department of Hepato-gastroenterology, Haut Lévêque Hospital, Pessac, France.
Gouttebel MC; Department of Oncology, Drôme Nord Hospital, Romans Sur Isère, France.
Malka D; Department of Hepato-gastroenterology, Gustave Roussy Cancer Campus, Villejuif, France.
Bachet JB; Department of Hepato-gastroenterology, Pitié-Salpêtrière Hospital, Paris, France.
Lepage C; Department of Hepato-gastroenterology, University Hospital of Dijon, EPICAD INSERM LNC-UMR 1231, University of Burgundy and Franche Comté, Dijon, France.
Taieb J; Department of Hepato-gastroenterology, Sorbonne Paris City, Paris Descartes University, Georges Pompidou European Hospital, Paris, France. Electronic address: .
Pokaż więcej
Corporate Authors :
PRODIGE 37 Investigators/Collaborators
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 Sep; Vol. 136, pp. 25-34. Date of Electronic Publication: 2020 Jul 02.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma/*drug therapy
Albumins/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Deoxycytidine/*analogs & derivatives
Paclitaxel/*administration & dosage
Pancreatic Neoplasms/*drug therapy
Adenocarcinoma/pathology ; Adult ; Aged ; Albumins/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Camptothecin/administration & dosage ; Camptothecin/adverse effects ; Camptothecin/analogs & derivatives ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Disease Progression ; Drug Substitution ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; France ; Humans ; Irinotecan/administration & dosage ; Irinotecan/adverse effects ; Leucovorin/administration & dosage ; Leucovorin/adverse effects ; Male ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Metastasis ; Paclitaxel/adverse effects ; Pancreatic Neoplasms/pathology ; Progression-Free Survival ; Treatment Outcome
SCR Protocol :
IFL protocol
Czasopismo naukowe
Tytuł :
Mechanistic Insight into Antiretroviral Potency of 2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention.
Autorzy :
Sun L; Henan Key Laboratory of Organic Functional Molecule and Drug Innovation, College of Life Science, Henan Normal University, Xinxiang 453007, China.
Peng Y; Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Yu W; College of Chemistry, Zhengzhou University, Zhengzhou 450001, China.
Zhang Y; Henan Key Laboratory of Organic Functional Molecule and Drug Innovation, College of Life Science, Henan Normal University, Xinxiang 453007, China.
Liang L; College of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang 453007, China.
Song C; College of Chemistry, Zhengzhou University, Zhengzhou 450001, China.
Hou J; College of Chemistry, Zhengzhou University, Zhengzhou 450001, China.
Qiao Y; College of Chemistry, Zhengzhou University, Zhengzhou 450001, China.
Wang Q; Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Chen J; Henan Key Laboratory of Organic Functional Molecule and Drug Innovation, College of Life Science, Henan Normal University, Xinxiang 453007, China.; Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.
Wu M; Henan Key Laboratory of Organic Functional Molecule and Drug Innovation, College of Life Science, Henan Normal University, Xinxiang 453007, China.; Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.
Zhang D; Henan Key Laboratory of Organic Functional Molecule and Drug Innovation, College of Life Science, Henan Normal University, Xinxiang 453007, China.; Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.
Li E; Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China.
Han Z; Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China.
Zhao Q; Department of Infection, Zhengzhou Sixth People's Hospital, Zhengzhou 450000, China.
Jin X; Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China.
Zhang B; HIT Center for Life Sciences, School of Life Science and Technology, Harbin Institute of Technology, Harbin 150080, China.
Huang Z; HIT Center for Life Sciences, School of Life Science and Technology, Harbin Institute of Technology, Harbin 150080, China.
Chai J; Henan Key Laboratory of Organic Functional Molecule and Drug Innovation, College of Life Science, Henan Normal University, Xinxiang 453007, China.; Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China.
Wang JH; Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.
Chang J; Henan Key Laboratory of Organic Functional Molecule and Drug Innovation, College of Life Science, Henan Normal University, Xinxiang 453007, China.; College of Chemistry, Zhengzhou University, Zhengzhou 450001, China.; College of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang 453007, China.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2020 Aug 13; Vol. 63 (15), pp. 8554-8566. Date of Electronic Publication: 2020 Aug 03.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-HIV Agents/*therapeutic use
Azides/*therapeutic use
Deoxycytidine/*analogs & derivatives
HIV Infections/*drug therapy
HIV-1/*drug effects
Lamivudine/*therapeutic use
Animals ; Anti-HIV Agents/pharmacokinetics ; Anti-HIV Agents/pharmacology ; Azides/pharmacokinetics ; Azides/pharmacology ; Deoxycytidine/pharmacokinetics ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; HIV Infections/metabolism ; HIV-1/physiology ; Humans ; Lamivudine/pharmacokinetics ; Lamivudine/pharmacology ; Macaca mulatta ; Models, Molecular ; Reverse Transcriptase Inhibitors/pharmacokinetics ; Reverse Transcriptase Inhibitors/pharmacology ; Reverse Transcriptase Inhibitors/therapeutic use ; Ubiquitination/drug effects
Czasopismo naukowe
Tytuł :
MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
Autorzy :
Shi Y; Department of Radiotherapy, Affiliated Hospital of Nantong University, Nantong 226001, China.
Wang Y; Department of Radiotherapy, Affiliated Hospital of Nantong University, Nantong 226001, China.
Qian J; Department of Radiotherapy, Affiliated Hospital of Nantong University, Nantong 226001, China.
Yan X; Department of Radiotherapy, Affiliated Hospital of Nantong University, Nantong 226001, China.
Han Y; Department of Radiotherapy, Affiliated Hospital of Nantong University, Nantong 226001, China.
Yao N; Department of Radiotherapy, Affiliated Hospital of Nantong University, Nantong 226001, China.
Ma J; Department of Radiotherapy, Affiliated Hospital of Nantong University, Nantong 226001, China. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2020 Oct 15; Vol. 259, pp. 118148. Date of Electronic Publication: 2020 Jul 25.
Typ publikacji :
Journal Article
MeSH Terms :
Antimetabolites, Antineoplastic/*pharmacology
DNA Modification Methylases/*biosynthesis
DNA Modification Methylases/*genetics
DNA Repair Enzymes/*biosynthesis
DNA Repair Enzymes/*genetics
Deoxycytidine/*analogs & derivatives
Drug Resistance, Neoplasm/*genetics
Pancreatic Neoplasms/*drug therapy
Tumor Suppressor Proteins/*biosynthesis
Tumor Suppressor Proteins/*genetics
Animals ; Autophagy/drug effects ; Cell Movement ; Cell Proliferation/drug effects ; DNA Modification Methylases/antagonists & inhibitors ; DNA Repair Enzymes/antagonists & inhibitors ; Deoxycytidine/pharmacology ; Drug Screening Assays, Antitumor ; Enzyme Inhibitors/pharmacology ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Male ; Mice ; Mice, Nude ; Neoplasm Invasiveness ; Pancreatic Neoplasms/pathology ; Purines/pharmacology ; Purines/therapeutic use ; Tumor Suppressor Proteins/antagonists & inhibitors ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Quercetin potentializes the respective cytotoxic activity of gemcitabine or doxorubicin on 3D culture of AsPC-1 or HepG2 cells, through the inhibition of HIF-1α and MDR1.
Autorzy :
Hassan S; Regenerative Nanomedicine, INSERM UMR 1260, FMTS, University of Strasbourg, Strasbourg, France.; Platform eBiocyt-UPS1401, Faculty of Pharmacy, University of Strasbourg, Strasbourg, France.
Peluso J; Platform eBiocyt-UPS1401, Faculty of Pharmacy, University of Strasbourg, Strasbourg, France.
Chalhoub S; Department of Integrative Structural Biology, Institut de Génétique et de Biologie Moléculaire et Cellulaire, INSERM, U964 CNRS UMR 7104, Université de Strasbourg, Strasbourg, France.
Idoux Gillet Y; Regenerative Nanomedicine, INSERM UMR 1260, FMTS, University of Strasbourg, Strasbourg, France.
Benkirane-Jessel N; Regenerative Nanomedicine, INSERM UMR 1260, FMTS, University of Strasbourg, Strasbourg, France.
Rochel N; Department of Integrative Structural Biology, Institut de Génétique et de Biologie Moléculaire et Cellulaire, INSERM, U964 CNRS UMR 7104, Université de Strasbourg, Strasbourg, France.
Fuhrmann G; Regenerative Nanomedicine, INSERM UMR 1260, FMTS, University of Strasbourg, Strasbourg, France.
Ubeaud-Sequier G; Regenerative Nanomedicine, INSERM UMR 1260, FMTS, University of Strasbourg, Strasbourg, France.; Platform eBiocyt-UPS1401, Faculty of Pharmacy, University of Strasbourg, Strasbourg, France.; Department of Pharmacy, Strasbourg University Hospital, Strasbourg, France.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Oct 14; Vol. 15 (10), pp. e0240676. Date of Electronic Publication: 2020 Oct 14 (Print Publication: 2020).
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*pharmacology
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Antioxidants/*pharmacology
Deoxycytidine/*analogs & derivatives
Doxorubicin/*pharmacology
Quercetin/*pharmacology
ATP Binding Cassette Transporter, Subfamily B/metabolism ; Adenocarcinoma/drug therapy ; Cell Hypoxia/drug effects ; Deoxycytidine/pharmacology ; Drug Resistance, Neoplasm/drug effects ; Gene Expression Regulation, Neoplastic/drug effects ; Hep G2 Cells ; Humans ; Hypoxia-Inducible Factor 1, alpha Subunit/metabolism ; Liver Neoplasms/drug therapy ; Pancreatic Neoplasms/drug therapy ; Tumor Microenvironment/drug effects
Czasopismo naukowe
Tytuł :
Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
Autorzy :
Dhar D; Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado.
Raina K; Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado.; Department of Pharmaceutical Sciences, South Dakota State University, Brookings, South Dakota.
Kumar D; Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado.
Wempe MF; Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado.
Bagby SM; Division of Medical Oncology, School of Medicine, University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado.
Pitts TM; Division of Medical Oncology, School of Medicine, University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado.
Orlicky DJ; Department of Pathology, University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado.
Agarwal C; Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado.
Messersmith WA; Division of Medical Oncology, School of Medicine, University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado.; University of Colorado Cancer Center, University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado.
Agarwal R; Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado.; University of Colorado Cancer Center, University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado.
Pokaż więcej
Źródło :
Molecular carcinogenesis [Mol Carcinog] 2020 Oct; Vol. 59 (10), pp. 1227-1240. Date of Electronic Publication: 2020 Aug 20.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Disease Models, Animal*
Carcinoma, Pancreatic Ductal/*drug therapy
Deoxycytidine/*analogs & derivatives
Drug Resistance, Neoplasm/*drug effects
Momordica charantia/*chemistry
Pancreatic Neoplasms/*drug therapy
Plant Extracts/*pharmacology
Animals ; Antimetabolites, Antineoplastic/pharmacology ; Apoptosis ; Carcinoma, Pancreatic Ductal/pathology ; Cell Proliferation ; Deoxycytidine/pharmacology ; Female ; Humans ; Mice ; Mice, Nude ; Neoplasm Invasiveness ; Pancreatic Neoplasms/pathology ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
A Gemcitabine Plus 5-Fluorouracil Combination Inhibits Gastric-Cancer Liver Metastasis in a PDOX Model: A Novel Treatment Strategy.
Autorzy :
Sugisawa N; AntiCancer, Inc., San Diego, CA, U.S.A.; Department of Surgery, University of California, San Diego, CA, U.S.A.; Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Nishino H; AntiCancer, Inc., San Diego, CA, U.S.A.; Department of Surgery, University of California, San Diego, CA, U.S.A.
Higuchi T; AntiCancer, Inc., San Diego, CA, U.S.A.; Department of Surgery, University of California, San Diego, CA, U.S.A.
Park JH; AntiCancer, Inc., San Diego, CA, U.S.A.; Department of Surgery, University of California, San Diego, CA, U.S.A.
Yamamoto J; AntiCancer, Inc., San Diego, CA, U.S.A.; Department of Surgery, University of California, San Diego, CA, U.S.A.
Tashiro Y; AntiCancer, Inc., San Diego, CA, U.S.A.; Department of Surgery, University of California, San Diego, CA, U.S.A.
Kawaguchi K; Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Bouvet M; Department of Surgery, University of California, San Diego, CA, U.S.A.
Unno M; Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan .
Hoffman RM; AntiCancer, Inc., San Diego, CA, U.S.A. .; Department of Surgery, University of California, San Diego, CA, U.S.A.
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2020 Oct; Vol. 40 (10), pp. 5393-5397.
Typ publikacji :
Journal Article
MeSH Terms :
Deoxycytidine/*analogs & derivatives
Fluorouracil/*pharmacology
Liver Neoplasms/*drug therapy
Stomach Neoplasms/*drug therapy
Animals ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Deoxycytidine/pharmacology ; Disease Models, Animal ; Humans ; Liver Neoplasms/pathology ; Mice ; Oxaliplatin/pharmacology ; Stomach/drug effects ; Stomach/pathology ; Stomach Neoplasms/pathology ; Xenograft Model Antitumor Assays
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies